ClinicalTrials.gg
RecruitingNCT07749716Updated Aug 27, 2026

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

A Phase 2 interventional study of Drug: VC005 tablets and VC005 tablets in Alopecia Areata, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Planned enrollment
15th of 22
120 · median 163
Started
2026
with 4 others
Phase 2
6 of 24
2 open now
Primary completion
2028-12
later than 10 of 12 live
Registered
23rd of 24
by date
Lead sponsor
2 of 24
Jiangsu vcare pharmaceutical technology co., LTD

Among the 24 studies in Alopecia Areata with a site in China, this one is the 15th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 10 of the 12 other live ones, and was the 23rd registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must fully understand the study, be willing and able to comply with all trial procedures, voluntarily participate in the clinical trial, and provide written by signing the informed consent form (ICF).
  • Subjects must be aged between 18 and 65 years (inclusive) at the time of ICF signing, regardless of gender.
  • Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period.
  • Subjects with a current diagnosis of acute diffuse alopecia areata (AA).
  • Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc.
  • Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    VC005 Tablets Low Dose group

    Drug: Drug: VC005 tablets

  • Experimental
    VC005 Tablets High Dose group

    Drug: VC005 tablets

  • Placebo comparator
    VC005 Tablets placebo group

    Drug: VC005 placebo tablets

Interventions

  • VC005 repeat administration for 24 weeks

  • VC005 repeat administration for 24 weeks

  • DrugVC005 placebo tablets

    VC005 placebo repeat administration for 24 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a Severity of Alopecia Tool (SALT) score ≤ 20

    Time frame: at Week 24 (W24)

07

Study locations

1 of 1 sites recruiting
  • The Peking University People's Hospital, Beijing, Beijng
    Beijing, Beijing Municipality, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's planned 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartActual
Aug 18, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07749716
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Aug 18, 2026
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

xiaojuan Lai
Contact
lai_xiaojuan@vcarepharmatech.com
+8615358160458
jianzhong Zhang
principal investigator · The Peking University People's Hospital, Beijing, Beijng
cheng zhou
principal investigator · The Peking University People's Hospital, Beijing, Beijng

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VC005

Start the discussion